Heron Therapeutics, Inc.
HRTX
$0.34
$0.000.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.99% | 1.48% | 7.36% | 12.60% | 9.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.99% | 1.48% | 7.36% | 12.60% | 9.78% |
| Cost of Revenue | 13.15% | 5.75% | -2.81% | -5.92% | -26.49% |
| Gross Profit | -5.27% | -0.89% | 13.69% | 25.15% | 47.13% |
| SG&A Expenses | 7.06% | 6.08% | 3.17% | 11.87% | 1.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.15% | 5.97% | 1.05% | 5.10% | -10.11% |
| Operating Income | -981.82% | -192.42% | 77.98% | 119.19% | 104.28% |
| Income Before Tax | -3,557.25% | -297.44% | -48.71% | 51.45% | 98.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3,557.25% | -297.44% | -48.71% | 51.45% | 98.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3,557.25% | -297.44% | -48.71% | 51.45% | 98.07% |
| EBIT | -981.82% | -192.42% | 77.98% | 119.19% | 104.28% |
| EBITDA | -345.53% | -568.17% | 97.52% | 169.45% | 113.67% |
| EPS Basic | -3,014.75% | -245.12% | -30.68% | 57.91% | 98.12% |
| Normalized Basic EPS | -2,041.03% | -177.37% | 37.63% | 102.74% | 103.04% |
| EPS Diluted | -974.16% | -210.27% | -43.78% | 51.53% | 94.51% |
| Normalized Diluted EPS | -4,831.25% | -153.38% | 32.85% | 97.01% | 101.25% |
| Average Basic Shares Outstanding | 20.35% | 14.76% | 9.25% | 3.52% | 1.96% |
| Average Diluted Shares Outstanding | 12.40% | 7.15% | 16.38% | 10.65% | 9.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |